To include your compound in the COVID-19 Resource Center, submit it here.

Hua starts U.S. Phase I trial of diabetes candidate

Hua Medicine Ltd. (HKEX:2552) began a Phase I trial of its dorzagliatin (sinogliatin,

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE